TH17 cells may be a potential biomarker to predict the risk of immune-related adverse events in patients with metastatic melanoma receiving the combination therapy of nivolumab, ipilimumab, and tocilizumab.
Health Professionals
Immune Checkpoint Inhibitors Potentially Curative for Melanoma
Ten-year follow up from the CheckMate 067 and KEYNOTE-006 trials confirm that patients with advanced melanoma can achieve durable responses from treatment with the PD1 inhibitors nivolumab and pembrolizumab and that a lack of disease progression at 3 years is strong indicator of long-term survival.
Survival Plateau Observed After ICI Therapy in Advanced Melanoma
Patients with advanced melanoma reach a plateau in survival after treatment with immune checkpoint inhibitors (ICIs), according to real-world data published in JAMA Network Open.
GPs essential to early diagnosis and treatment of melanoma
As Australian patients begin to spend more time in the sun, the Royal Australian College of GPs (RACGP) has urged patients to organise a skin check with their GP to ensure dangerous skin cancers are detected and treated early.